UK markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
103.29+3.02 (+3.01%)
At close: 04:00PM EDT
103.01 -0.28 (-0.27%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close100.27
Bid102.50 x 1100
Ask103.30 x 1000
Day's range100.97 - 104.74
52-week range95.02 - 217.25
Avg. volume3,862,638
Market cap39.311B
Beta (5Y monthly)1.62
PE ratio (TTM)34.43
EPS (TTM)3.00
Earnings date01 Nov 2023 - 06 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est181.35
  • Motley Fool

    Moderna's Shares Could Take Off if These 2 Things Happen

    Moderna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined.

  • Motley Fool

    Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine

    Once a relatively unknown biotech company, Moderna (NASDAQ: MRNA) became a household name when it became one of the first companies to offer a vaccine for the COVID-19 virus. At its peak, Moderna saw quarterly revenue of $7 billion as it sold vaccines to the world. Its stock price followed suit, reaching an all-time high of $484 in mid-2021.

  • Motley Fool

    If I Could Only Buy 3 Stocks in 2023, I'd Pick These

    CRISPR Therapeutics (NASDAQ: CRSP) specializes in gene editing, or the repair of faulty genes responsible for disease. Right now, CRISPR is heading for its biggest moment ever -- a regulatory decision on what may become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March.